Novartis reveals new data on rapid symptom relief and long-term control in skin diseases at AAD 2026.

At the AAD 2026 meeting, Novartis presented over 20 abstracts showcasing new data on its immunology portfolio, including early symptom relief from Rhapsido in chronic spontaneous urticaria and long-term efficacy of Cosentyx in hidradenitis suppurativa and psoriasis. The data highlight rapid itch and hives improvement within one week for Rhapsido and sustained benefits of Cosentyx over 4-5 years. These findings reinforce Novartis' commitment to advancing treatments for chronic skin conditions and improving patient quality of life.